natgillin/translations-raw huggingface dataset:
Interruption or discontinuation of lenalidomide should be considered for other forms of skin reaction depending on severity.
Pri drugih oblikah kožnih reakcij pride v poštev prekinitev dajanja lenalidomida ali njegova ukinitev, odvisno od njihove izraženosti.
Hepatic failure, including fatal cases, has been reported in patients treated with lenalidomide in combination therapy: acute hepatic failure, toxic hepatitis, cytolytic hepatitis, cholestatic hepatitis, and mixed cytolytic/cholestatic hepatitis have been reported.
Pri bolnikih, zdravljenih z lenalidomidom v kombinirani terapiji, so poročali o odpovedi jeter, vključno s smrtnimi primeri: poročali so o akutni odpovedi jeter, toksičnem hepatitisu, citolitičnem hepatitisu, holestatskem hepatitisu in mešanem citolitičnem/holestatskem hepatitisu.
In this pooled extended follow-up analysis, the median TTP was 60.1 weeks (95% CI: 44.3, 73.1) in patients treated with len/dex (N = 353) versus 20.1 weeks (95% CI: 17.7, 20.3) in patients treated with placebo/dex (N = 351).
V tej zbrani podaljšani sledilni analizi je bila mediana TTP 60,1 tedna (95 % IZ: 44,3; 73,1) pri bolnikih, ki so prejemali len/deks (n = 353) v primerjavi z 20,1 tedna (95 % IZ: 17,7; 20,3) pri bolnikih, ki so prejemali placebo/deks (n = 351).
• Educational Health Care Professional's kit
• izobraževalni paket za zdravstvene delavce,
The recommended dose of dexamethasone is 40 mg orally once daily on days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for the first 4 cycles of therapy and then 40 mg once daily on days 1 to 4 every 28 days.
Priporočeni odmerek deksametazona je 40 mg peroralno enkrat na dan od 1. do 4. dne, od 9. do 12. dne in od 17. do 20. dne v 28-dnevnih ciklih v prvih štirih ciklih zdravljenja, nato pa 40 mg enkrat na dan od 1. do 4. dne vsakih 28 dni.
It has also been shown to delay multiple myeloma from coming back following treatment.
Izkazalo se je tudi, da zdravilo Lenalidomide odloži ponovitev diseminiranega plazmocitoma po zdravljenju.
Severe renal impairment (CLcr < 30 mL/min, not requiring dialysis)
Huda okvara ledvic (CLcr < 30 ml/min, dializa ni potrebna)
The following table is derived from data gathered during the multiple myeloma studies with combination therapy.
Naslednja preglednica vsebuje podatke, zbrane med študijami diseminiranega plazmocitoma s kombiniranim zdravljenjem.
Tabulated summary of post-marketing adverse reactions
Povzetek neželenih učinkov v obdobju trženja v obliki preglednice
Hypokalaemia◊, Hyperglycaemia, Hypocalcaemia◊, Diabetes mellitus◊, Hypophosphataemia, Hyponatraemia◊, Hyperuricaemia, Gout, Decreased appetite, Weight decreased
pogosti hipokaliemija◊, hiperglikemija◊, hipokalciemija◊, sladkorna bolezen◊, hipofosfatemija, hiponatriemija◊, hiperurikemija, protin, zmanjšan apetit, zmanjšanje telesne mase
Overall survival (months) Mediana OS time, months (95% CI)b
Celokupno preživetje (meseci) Medianaa časa OS, meseci (95 % IZ)b
• you must use effective methods of contraception for 4 weeks before starting treatment, during treatment, and until 4 weeks after stopping treatment.
• 4 tedne pred začetkom zdravljenja, med zdravljenjem in 4 tedne po koncu zdravljenja morate uporabljati zanesljivo kontracepcijsko metodo.
Congestive cardiac failure◊, Tachycardia, Cardiac failure◊, Myocardial ischemia◊
atrijska fibrilacija◊, kongestivno srčno popuščanje◊, tahikardija, srčno popuščanje◊, ishemija miokarda◊
Lenalidomide efficacy and safety have been evaluated in five phase III studies in newly diagnosed multiple myeloma, two phase III studies in relapsed refractory multiple myelomaas described below.
Varnost in učinkovitost lenalidomida so ocenili v petih študijah faze III pri novo diagnosticiranem diseminiranem plazmocitomu in v dveh študijah faze III pri ponovljenem, na zdravljenje neodzivnem diseminiranem plazmocitomu, kot je opisano v nadaljevanju.
The demographic and disease-related characteristics were balanced across both arms.
Demografske značilnosti in z boleznijo povezane značilnosti bolnikov so bile v obeh skupinah primerljive.
Patients with known risk factors - including prior thrombosis - should be closely monitored, and action should be taken to try to minimize all modifiable risk factors (eg.
Bolnike z znanimi dejavniki tveganja, vključno s predhodnimi trombozami, je potrebno skrbno spremljati in z ustreznimi ukrepi poskusiti zmanjšati tiste dejavnike tveganja, na katere lahko vplivamo (npr. kajenje, hipertenzija in hiperlipidemija).
• an anti-inflammatory medicine called ‘dexamethasone'
• s protivnetnim zdravilom, ki se imenuje ‘deksametazon';
Acute hepatic failure^, Hepatitis toxic^, Cytolytic hepatitis^, Cholestatic hepatitis^, Mixed cytolytic/cholestatic hepatitis^
Bolezni jeter, žolčnika in žolčevodov neznana pogostnost akutna odpoved jeter^, toksični hepatitis^, citolitični hepatitis^, holestatični hepatitis^, mešani citolitični/holestatični hepatitis^
Check list for physicians ensuring that patients receive the appropriate counselling concerning the treatment, contraceptive methods and pregnancy prevention appropriate for their sex and childbearing status
• obrazec za poročanje nosečnosti; Kontrolni seznam za zdravnike, ki zagotavlja, da je bil bolnik deležen ustreznega svetovanja o zdravljenju, kontracepcijskih metodah in preprečevanju nosečnosti, ki ustreza spolu in statusu zmožnosti zanositve; Obrazce za poročanje o neželenih učinkih.
Cholestasis◊, Abnormal liver function tests◊
pogosti holestaza◊, nenormalni testi delovanja jeter◊
No dose adjustment is proposed for patients older than 75 years who are treated with lenalidomide in combination with melphalan and prednisone.
Za bolnike, starejše od 75 let, zdravljene z lenalidomidom v kombinaciji z melfalanom in prednizonom, ne predlagajo prilagajanja odmerka.
Fatigue, dizziness, somnolence, vertigo and blurred vision have been reported with the use of lenalidomide.
Pri uporabi lenalidomida so poročali o utrujenosti, omotici, somnolenci, vrtoglavici in zamegljenem vidu.
Not Known
ni navedbe
A majority of lenalidomide is eliminated through urinary excretion.
Večina lenalidomida se izloči preko ledvic.
• Abnormal liver test results
• nenormalni rezultati delovanja jeter;
The results of PFS at unblinding, following a preplanned interim analysis, using a cut-off of 7 July 2010 (31.4 months follow up) showed a 48% reduction in risk of disease progression or death favoring lenalidomide (HR = 0.52; 95% CI 0.41, 0.66; p <0.001).
Rezultati PFS ob prekinitvi dvojno slepega zdravljenja po vnaprej načrtovani vmesni analizi, z datumom zaključka zbiranja podatkov 7. julij 2010 (31,4 meseca spremljanja), so pokazali 48% zmanjšanje tveganja napredovanja bolezni ali smrti v prid lenalidomidu (HR = 0,52; 95 % IZ 0,41; 0,66; p <0,001).
The primary efficacy endpoint in the study was progression free survival (PFS).
Primarni cilj študije za dokaz učinkovitosti je bilo obdobje brez napredovanja bolezni (PFSprogression free survival ).
Decrease by one dose level when dosing resumed at next cycle ª If Dose limiting toxicity (DLT) occurs on > day15 of a cycle, lenalidomide dosing will be interrupted for at least the remainder of the current 28-day cycle.
Priporočen potek zdravljenja zmanjša na < 25 x 109/l prekinite zdravljenje z lenalidomidom za preostali del ciklaª vrne na ≥ 50 x 109/l ko nadaljujete zdravljenje v naslednjem ciklu, zmanjšajte odmerek za eno raven odmerka ª Če toksičnost, ki omejuje odmerek (DLT - dose limiting toxicity), nastopi po 15. dnevu cikla, prekinite zdravljenje z lenalidomidom vsaj za preostanek trenutnega 28-dnevnega cikla.
Common Deafness (Including Hypoacusis), Tinnitus
Ušesne bolezni, vključno z motnjami labirinta pogosti gluhost (vključno s hipoakuzo), tinitus
◊ Adverse reactions reported as serious in clinical trials in patients with NDMM who had undergone ASCT * Applies to serious adverse drug reactions only ^ See section 4.8 description of selected adverse reactions a “Pneumonias” combined AE term includes the following PTs: Bronchopneumonia, Lobar pneumonia, Pneumocystis jiroveci pneumonia, Pneumonia, Pneumonia klebsiella, Pneumonia legionella, Pneumonia mycoplasmal, Pneumonia pneumococcal, Pneumonia streptococcal, Pneumonia viral, Lung disorder, Pneumonitis b “Sepsis” combined AE term includes the following PTs: Bacterial sepsis, Pneumococcal sepsis, Septic shock, Staphylococcal sepsis c “Peripheral neuropathy” combined AE term includes the following preferred terms (PTs): Neuropathy peripheral, Peripheral sensory neuropathy, Polyneuropathy d “Deep vein thrombosis” combined AE term includes the following PTs: Deep vein thrombosis, Thrombosis, Venous thrombosis
◊ Neželeni učinki, za katere v kliničnih preskušanjih pri bolnikih z NDDP, pri katerih je bila opravljena ASCT, poročajo, da so resni * Se nanaša samo na resne neželene učinke ^ Glejte poglavje 4.8 opis izbranih neželenih učinkov a “Pljučnice”, kombiniran izraz za neželene dogodke, vključuje naslednje preferenčne izraze (PT - preferred terms): bronhopnevmonija, lobarna pnevmonija, pnevmonija Pneumocystis jiroveci, pnevmonija, pnevmonija klebsiela, pnevmonija legionela, mikoplazmatska pnevmonija, pnevmokokna pnevmonija, streptokokna pnevmonija, virusna pnevmonija, pljučna bolezen, pnevmonitis.
HR [95% CI]; p-value MPR+R vs MPp+p MPR+R vs MPR+p MPR+p vs MPp +p Overall survival (months) Mediana OS time, months (95% CI)
HR [95 % IZ]; vrednost p MPR+R proti MPp+p MPR+R proti MPR+p MPR+p proti MPp +p Celokupno preživetje (meseci) Medianaa časa OS, meseci (95 % IZ)
Lenalidomide received by subjects in the placebo arm who crossed over prior to PD upon study unblinding was not considered as a second-line therapy.
Lenalidomid, ki so ga prejeli preiskovanci v skupini s placebom, ki so zamenjali skupino po prekinitvi dvojno slepega zdravljenja pred napredovanjem bolezni, se ni štel za zdravljenje druge izbire.
Lenalidomide is excreted by the kidneys.
Lenalidomid se izloča skozi ledvice.
The median overall PFS was 33.9 months (95% CI NE, NE) in the lenalidomide arm versus 19.0 months (95% CI 16.2, 25.6) in the placebo arm.
Mediana celokupnega PFS je bila 33,9 meseca (95 % IZ NE; NE) v skupini z lenalidomidom in 19,0 meseca (95 % IZ 16,2; 25,6) v skupini s placebom.
Common Pulmonary embolism◊,*
Žilne bolezni pogosti pljučna embolija◊,*
^see section 4.8 description of selected adverse reactions
^Glejte poglavje 4.8 opis izbranih neželenih učinkov.
Patients >75 years received a dexamethasone dose of 20 mg once daily on days 1, 8, 15, and 22 of each 28-day cycle.
Bolniki, starejši od 75 let, so prejemali odmerek deksametazona 20 mg enkrat na dan 1., 8., 15. in 22. dne vsakega 28-dnevnega cikla.
In the CALGB 100104 study, the adverse reactions observed more frequently with lenalidomide maintenance than placebo were neutropenia (79.0% [71.9% after the start of maintenance treatment]), thrombocytopenia (72.3% [61.6%]), diarrhoea (54.5% [46.4%]), rash (31.7% [25.0%]), upper respiratory tract infection (26.8% [26.8%]), fatigue (22.8% [17.9%]), leucopenia (22.8% [18.8%]) and anaemia (21.0% [13.8%]).
V študiji CALGB 100104 so bili neželeni učinki, ki so jih opazili pogosteje pri vzdrževalnem zdravljenju z lenalidomidom kot pri placebu, nevtropenija (79,0 % [71,9 % po začetku vzdrževalnega zdravljenja]), trombocitopenija (72,3 % [61,6 %]), driska (54,5 % [46,4 %]), izpuščaj (31,7 % [25,0 %]), okužba zgornjih dihal (26,8 % [26,8 %]), utrujenost (22,8 % [17,9 %]), levkopenija (22,8 % [18,8 %]) in anemija (21,0 % [13,8 %]).
Lenalidomide interruption or discontinuation should be considered for grade 2 or 3 skin rash.
Pri kožnem izpuščaju 2. ali 3. stopnje je treba razmisliti o prekinitvi ali ukinitvi zdravljenja z lenalidomidom.
In patients receiving lenalidomide in combination with dexamethasone until progression or for 18 months, the hematologic SPM incidence rate (0.16 per 100 person-years) was not increased as compared to thalidomide in combination with melphalan and prednisone (0.79 per 100 person-years).
Pri bolnikih, ki so prejemali lenalidomid v kombinaciji z deksametazonom do napredovanja bolezni ali 18 mesecev dolgo, se incidenca hematoloških SPM (0,16 na 100 oseb-let) ni zvečala v primerjavi s talidomidom v kombinaciji z melfalanom in prednizonom (0,79 na 100 oseb-let).
- capsule shell: gelatin, titanium dioxide (E171)
ovojnica kapsule: želatina, titanov dioksid (E171)
End Stage Renal Disease (ESRD) (CLcr < 30 mL/min, requiring dialysis)
Končna odpoved ledvic (ESRD) (CLcr < 30 ml/min, dializa je potrebna)
e Exploratory endpoint (PFS2) f The median is the univariate statistic without adjusting for censoring.
f Mediana je univariaten podatek brez prilagajanja samo delno znanim podatkom.
The median overall survival in the extended follow-up analysis of the pooled studies is 164.3 weeks (95% CI: 145.1, 192.6) in patients treated with len/dex versus 136.4 weeks (95% CI: 113.1, 161.7) in patients treated with placebo/dex.
Mediana celokupnega preživetja v podaljšani sledilni analizi zbranih študij je bila pri bolnikih, ki so se zdravili z len/deks, 164,3 tedna (95 % IZ: 145,1; 192,6), pri bolnikih, ki so se zdravili s placebom/deks, pa 136,4 tedna (95 % IZ: 113,1; 161,7).
Caution should be exercised when lenalidomide is used in patients previously infected with HBV, including patients who are anti-HBc positive but HBsAg negative.
Za bolnike, ki imajo pozitiven test okužbe s HBV, priporočajo posvet z zdravnikom, ki ima izkušnje z zdravljenjem hepatitisa B. Previdnost je potrebna, kadar uporabljamo lenalidomid pri bolnikih, ki so bili predhodno okuženi s HBV, vključno z bolniki, ki so anti-HBc pozitivni, a HBsAg negativni.
Common Sepsis◊,b, Bacteraemia, Lung infection◊, Lower respiratory tract infection bacterial, Bronchitis◊, Influenza◊, Gastroenteritis◊, Herpes zoster◊, Infection◊
zelo pogosti pljučnice◊, a, nevtropenična okužba pogosti sepsa◊, b, bakteriemija, okužba pljuč◊, bakterijska okužba spodnjih dihal, bronhitis◊, gripa◊, gastroenteritis◊, herpes zoster◊, okužba◊
• National or other applicable specific arrangements for a prescription for Lenalidomide Accord to be dispensed
• nacionalne in druge ustrezne dogovore glede predpisovanja in izdajanja zdravila Lenalidomide
The risk of ATE is lower in patients with multiple myeloma treated with lenalidomide monotherapy than in patients with multiple myeloma treated with lenalidomide in combination therapy.
Tveganje arterijske trombembolije je manjše pri bolnikih z diseminiranim plazmocitomom, zdravljenih z monoterapijo z lenalidomidom, kot pri bolnikih z diseminiranim plazmocitomom, zdravljenih z lenalidomidom v kombinirani terapiji.
Capsule contents
Trda kapsula
For men taking lenalidomide lenalidomide passes into human semen.
Lenalidomid prehaja v človeško spermo.
Lenalidomide Accord contains lactose
Zdravilo Lenalidomide Accord vsebuje laktozo
Lenalidomide is present in human semen at extremely low levels during treatment and is undetectable in human semen 3 days after stopping the substance in the healthy subject (see section 5.2).
Med zdravljenjem je lenalidomid prisoten v humani spermi v izredno nizkih koncentracijah, 3 dni po ukinitvi zdravila pa učinkovine v spermi zdrave osebe ni več mogoče zaznati (glejte poglavje 5.2).
In clinical trials of newly diagnosed multiple myeloma patients not eligible for transplant, a 4.9-fold increase in incidence rate of hematologic SPM (cases of acute myeloid leukaemia [AML], myelodysplastic syndrome [MDS)]) has been observed in patients receiving lenalidomide in combination with melphalan and prednisone until progression (1.75 per 100 person-years) compared with melphalan in combination with prednisone (0.36 per 100 person-years).
V kliničnih preskušanjih bolnikov z novo diagnosticiranim diseminiranim plazmocitomom, ki niso bili primerni za presaditev, so ugotovili 4,9-kratno zvečanje incidence hematoloških SPM (primeri akutne mieloične levkemije [AML], mielodisplastični sindrom [MDS]) pri bolnikih, ki so prejemali lenalidomid v kombinaciji z melfalanom in prednizonom do napredovanja bolezni (1,75 na 100 oseblet) v primerjavi z melfalanom v kombinaciji s prednizonom (0,36 na 100 oseb-let).
Tabulated summary for monotherapy in MM
Povzetek za monoterapijo pri DP v obliki preglednice
Patients in both treatment groups took 40 mg of dexamethasone orally once daily on days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for the first 4 cycles of therapy.
Bolniki v obeh skupinah zdravljenja so v prvih 4 ciklih zdravljenja jemali 40 mg deksametazona enkrat na dan od 1. do 4. dne, od 9. do 12. dne in od 17. do 20. dne v vsakem 28-dnevnem ciklu.
The PFS benefit was observed both in the subgroup of patients with CR and in the subgroup of patients who had not achieved a CR.
Izboljšani PFS so ugotovili v podskupini bolnikov s popolnim odgovorom in podskupini bolnikov, ki niso dosegli popolnega odgovora.
What you need to know before you take Lenalidomide Accord Do not take Lenalidomide Accord :
Kaj morate vedeti, preden boste vzeli zdravilo Lenalidomide Accord
• Bleeding from the gums, stomach, or bowels
• krvavitev dlesni, želodca ali črevesa;
• Multiple myeloma: patients with at least one prior therapy The combination of lenalidomide with dexamethasone in multiple myeloma patients with at least one prior therapy is associated with a higher incidence of grade 4 neutropenia (5.1% in lenalidomide/dexamethasone-treated patients compared with 0.6% in placebo/dexamethasone-treated patients; see section 4.8).
• Diseminirani plazmocitom: bolniki z vsaj eno predhodno terapijo Pri bolnikih z diseminiranim plazmocitomom z vsaj eno predhodno terapijo je kombinacija lenalidomida in deksametazona povezana s povečano incidenco nevtropenije 4. stopnje (5,1 % pri bolnikih, ki so prejemali lenalidomid/deksametazon, v primerjavi z 0,6 % pri bolnikih, ki so prejemali placebo/deksametazon; glejte poglavje 4.8).
The risk of occurrence of hematologic SPM must be taken into account before initiating treatment with lenalidomide either in combination with melphalan or immediately following high-dose melphalan and ASCT.
Pred uvedbo zdravljenja z lenalidomidom, v kombinaciji z melfalanom ali takoj po velikem odmerku melfalana in ASCT, je treba upoštevati tveganje hematoloških SPM.
The median overall PFS was 40.1 months (95% CI 35.7, 42.4) in the lenalidomide arm versus 22.8 months (95% CI 20.7, 27.4) in the placebo arm.
Mediana celokupnega PFS je bila 40,1 meseca (95 % IZ 35,7; 42,4) v skupini z lenalidomidom in 22,8 meseca (95 % IZ 20,7; 27,4) v skupini s placebom.
In patients with multiple myeloma, the combination of lenalidomide with dexamethasone is associated with an increased risk of arterial thromboembolism (predominantly myocardial infarction and cerebrovascular event) and was seen to a lesser extent with lenalidomide in combination with melphalan and prednisone.
Pri bolnikih z diseminiranim plazmocitomom je kombinacija lenalidomida z deksametazonom povezana z zvečanim tveganjem arterijske trombembolije (predvsem miokardnega infarkta in cerebrovaskularnih dogodkov), ki so jo opazili v manjši meri pri lenalidomidu v kombinaciji z melfalanom in prednizonom.
An increased risk of DVT and PE is associated with the use of the combination of lenalidomide with dexamethasone in patients with multiple myeloma, and to a lesser extent in patients treated with lenalidomide in combination with melphalan and prednisone or in patients with multiple myeloma, treated with lenalidomide monotherapy (see section 4.5).
Zvečano tveganje globoke venske tromboze (GVT) in pljučne embolije (PE) je povezano z uporabo kombinacije lenalidomida z deksametazonom pri bolnikih z diseminiranim plazmocitomom in v manjšem obsegu pri bolnikih, zdravljenih z lenalidomidom v kombinaciji z melfalanom in prednizonom ali pri bolnikih z diseminiranim plazmocitomom, zdravljenih z monoterapijo z lenalidomidom (glejte poglavje 4.5).
Lenalidomide in combination with dexamethasone until disease progression in patients who are not eligible for transplant
Lenalidomid v kombinaciji z deksametazonom do napredovanja bolezni pri bolnikih, ki niso primerni za presaditev
Newly diagnosed multiple myeloma: patients who have undergone ASCT treated with lenalidomide maintenance
Novo diagnosticirani diseminirani plazmocitom: bolniki, pri katerih je bila opravljena ASCT, zdravljeni z vzdrževalnim zdravljenjem z lenalidomidom
A.
IN
Lenalidomide Accord 7.5 mg, Lenalidomide Accord 20 mg and Lenalidomide Accord 25 mg hard capsules
Lenalidomide Accord 7,5 mg, Lenalidomide Accord 20 mg in Lenalidomide Accord 25 mg trde kapsule
Dose level -5
Raven odmerka -5
Odds ratio [95% CI], p-value b
Razmerje obetov [95 % IZ], vrednost pb
The observed adverse reactions which occurred more frequently with lenalidomide and dexamethasone than placebo and dexamethasone in pooled multiple myeloma clinical trials (MM-009 and MM-010) were fatigue (43.9%), neutropenia (42.2%), constipation (40.5%), diarrhoea (38.5%), muscle cramp (33.4%), anaemia (31.4%), thrombocytopenia (21.5%), and rash (21.2%).
Neželeni učinki, ki so se pogosteje pojavili z lenalidomidom in deksametazonom kot s placebom in deksametazonom v združenih kliničnih preskušanjih pri diseminiranem plazmocitomu (MM-009 in MM-010), so bili utrujenost (43,9 %), nevtropenija (42,2 %), zaprtje (40,5 %), driska (38,5 %), mišični krči (33,4 %), anemija (31,4 %), trombocitopenija (21,5 %) in izpuščaj (21,2 %).
Patients randomised to the lenalidomide/standard dose dexamethasone arm received lenalidomide 25 mg/day, days 1 to 21 every 28 days plus dexamethasone 40 mg/day on days 1 to 4, 9 to 12, and 17 to 20 every 28 days for the first four cycles.
Bolniki, ki so bili randomizirani na skupino lenalidomida/deksametazona v standardnem odmerku, so prejemali lenalidomid 25 mg/dan od 1. do 21. dne vsakih 28 dni plus deksametazon 40 mg/dan od 1. do 4. dne, od 9. do 12. dne in od 17. do 20. dne vsakih 28 dni prve štiri cikle.
TLS and tumour flare reaction (TFR) have commonly been observed in patients with chronic lymphocytic leukemia (CLL), and uncommonly in patients with lymphomas, who were treated with lenalidomide.
Sindrom tumorske lize in z zdravljenjem povzročeni zagon rakave bolezni prehodne narave (TFR) so pogosto ugotovili pri bolnikih s kronično limfocitno levkemijo (KLL), občasno pa pri bolnikih z limfomi, ki so se zdravili z lenalidomidom.
Very Common Depression, Insomnia Uncommon Loss of libido
Psihiatrične motnje zelo pogosti depresija, nespečnost občasni izguba libida pogosti depresija, nespečnost
Lenalidomide in combination with dexamethasone in patients who are not eligible for stem cell transplantation
Lenalidomid v kombinaciji z deksametazonom pri bolnikih, ki niso primerni za presaditev matičnih celic
Patients randomised to the lenalidomide/low dose dexamethasone arm received lenalidomide 25 mg/day, days 1 to 21 every 28 days plus low dose dexamethasone - 40 mg/day on days 1, 8, 15, and 22 every 28 days.
Bolniki, randomizirani na skupino lenalidomida/deksametazona v majhnem odmerku, so prejemali lenalidomid 25 mg/dan od 1. do 21. dne vsakih 28 dni plus deksametazon v majhnem odmerku - 40 mg/dan na 1., 8., 15. in 22. dan vsakih 28 dni.
Overall survival Mediana OS time, months (95% CI)b
Celokupno preživetje Medianaa časa OS, meseci (95 % IZ)b
In patients with multiple myeloma, , treatment with lenalidomide monotherapy was associated with a lower risk of venous thromboembolism (predominantly deep vein thrombosis and pulmonary embolism) than in patients with multiple myeloma treated with lenalidomide in combination therapy (see sections 4.5 and 4.8).
Pri bolnikih z diseminiranim plazmocitomom je monoterapija z lenalidomidom povezana z manjšim tveganjem venske trombembolije (predvsem globoke venske tromboze in pljučne embolije) kot pri bolnikih z diseminiranim plazmocitomom, zdravljenih z lenalidomidom v kombinirani terapiji (glejte poglavji 4.5 in 4.8).
There was no increase in peripheral neuropathy observed with long term use of lenalidomide for the treatment of newly diagnosed multiple myeloma.
Pri dolgoročni uporabi lenalidomida za zdravljenje novo diagnosticiranega diseminiranega plazmocitoma niso ugotovili zvečanja periferne nevropatije.